Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
Aspiration
FAERS
GLP-1 receptor agonist
Hair loss
Pharmacovigilance
Suicidality
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
accepted:
28
07
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
aheadofprint
Résumé
With the increasing popularity of glucagon-like peptide 1 receptor agonists (GLP1-RAs), numerous safety concerns arose pertaining to suicide, hair loss, and aspiration risks. We attempted to validate these concerns. We queried four pharmacovigilance databases to compare GLP1-RAs to sodium-glucose transporter 2 inhibitors (SGLT2is) with respect to these adverse events (AE): the FDA Adverse Event Reporting System (FAERS), the Australian Database of Adverse Event Notifications (DAEN), the European Medicines Agency's (EudraVigilance), and the World Health Organization-Vigibase. OpenVigil 2.1 was utilized to perform a disproportionality analysis for GLP1-RAs, SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas, metformin, and insulin. The following indices were extracted from the FAERS database from Q4/2003 until Q3/2023: relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (χ No positive signals were observed between GLP1-RAs and either suicide, hair loss, or aspiration risks. Semaglutide [ROR = 0.60 (0.51-0.71)] and liraglutide [ROR = 0.28 (0.23-0.35)] had higher suicidal events than DPP4is and SGLT2is. GLP1-RAs were the most reported class with hair loss [ROR = 0.61 (0.60-0.64)], and semaglutide, liraglutide, and dulaglutide were the three leading medications. GLP1-RAs ranked lower with aspiration events, which were led by sitagliptin and DPP4is as a group. GLP1-RAs exhibit higher reporting of suicide, hair loss, and aspiration events when compared to several other antidiabetic medications despite not meeting the criteria for positive signals yet. This warrants intensive monitoring and reporting.
Identifiants
pubmed: 39264502
doi: 10.1007/s10557-024-07613-w
pii: 10.1007/s10557-024-07613-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19. https://doi.org/10.1016/j.metabol.2013.09.010 .
doi: 10.1016/j.metabol.2013.09.010
pubmed: 24140094
Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. https://doi.org/10.1056/NEJMoa2306963 .
doi: 10.1056/NEJMoa2306963
pubmed: 37622681
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563 .
doi: 10.1056/NEJMoa2307563
pubmed: 37952131
He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513. https://doi.org/10.1001/jamainternmed.2022.0338 .
doi: 10.1001/jamainternmed.2022.0338
pubmed: 35344001
pmcid: 8961394
Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891–900. https://doi.org/10.1111/dom.15382 .
doi: 10.1111/dom.15382
pubmed: 38018310
Dillinger K. FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss. In: CNN. 2024. https://www.cnn.com/2024/01/03/health/glp1-agonist-side-effects-fda/index.html . Accessed 7 Feb 2024.
Reuters. E.U. investigates Ozempic, Saxenda after suicidal thoughts reported. In: NBC News. 2023. https://www.nbcnews.com/news/world/eu-investigates-ozempic-saxenda-suicidal-thoughts-reported-rcna93552 . Accessed 7 Feb 2024.
Pelc C. Can GLP-1 drugs Ozempic and Wegovy cause suicidal ideation, hair loss? In: MedicalNewsToday. 2024. https://www.medicalnewstoday.com/articles/ozempic-wegovy-side-effects-suicidal-ideation-hair-loss . Accessed 7 Feb 2024.
Manalac T. FDA probes GLP-1 receptor agonists on reports of suicidal thoughts, hair loss. In: BioSpace. 2024. https://www.biospace.com/article/novo-lilly-weight-loss-drugs-under-fda-scrutiny-for-suicidal-thoughts-hair-loss/ . Accessed 8 Feb 2024.
EMA statement on ongoing review of GLP-1 receptor agonists. In: European Medicines Agency. 2023. https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists . Accessed 8 Feb 2024.
Semaglutide Responsible Use | Official Website. In: novoMEDLINK. https://www.novomedlink.com/semaglutide.html . Accessed 8 Feb 2024.
Pozsgai K, Szűcs G, Kőnig-Péter A, et al. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: a descriptive study. Front Pharmacol. 2022;13:964399. https://doi.org/10.3389/fphar.2022.964399 .
doi: 10.3389/fphar.2022.964399
pubmed: 36147337
pmcid: 9485933
Böhm R, Von Hehn L, Herdegen T et al. OpenVigil FDA – inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLOS ONE. 2016;11(6):e0157753. https://doi.org/10.1371/journal.pone.0157753 .
Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug. 2001;10(6):483–6. https://doi.org/10.1002/pds.677 .
doi: 10.1002/pds.677
Ramya. 46: The Information Component | Pharmacovigilance. In: All About Pharmacovigilance. 2020. https://allaboutpharmacovigilance.org/46-the-information-component/ . Accessed 8 Feb 2024.
Obesity Medicines & Food Industry Impact. In: Morgan Stanley. 2023. https://www.morganstanley.com/ideas/obesity-drugs-food-industry . Accessed 8 Feb 2024.
Chen C, Zhou R, Fu F, Xiao J. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatr. 2023;66(1):e99. https://doi.org/10.1192/j.eurpsy.2023.2474 .
doi: 10.1192/j.eurpsy.2023.2474
Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168–76. https://doi.org/10.1038/s41591-023-02672-2 .
doi: 10.1038/s41591-023-02672-2
pubmed: 38182782
pmcid: 11034947
O'Neil PM, Aroda VR, Astrup A et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19(11):1529–36. https://doi.org/10.1111/dom.12963 .
Mui JV, Li L, Chou OHI, et al. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong. Acta Diabetol. 2023;60(7):917–27. https://doi.org/10.1007/s00592-023-02063-6 .
doi: 10.1007/s00592-023-02063-6
pubmed: 37000300
pmcid: 10198893
Ruggiero R, Mascolo A, Spezzaferri A, et al. Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European pharmacovigilance database. Pharmaceuticals. 2024;17(2):147. https://doi.org/10.3390/ph17020147 .
doi: 10.3390/ph17020147
pubmed: 38399362
pmcid: 10892952
McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024;23(1):47–55. https://doi.org/10.1080/14740338.2023.2295397 .
doi: 10.1080/14740338.2023.2295397
pubmed: 38087976
Andrade C. Metformin as a possible intervention for cardiometabolic risks in pediatric subjects exposed to antipsychotic drugs: (clinical and pricatical psychopharmacology). J Clin Psychiatry. 2016;77(10):1362–4. https://doi.org/10.4088/JCP.16f11196 .
doi: 10.4088/JCP.16f11196
pubmed: 27788311
Guirguis A, Chiappini S, Papanti PG, et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024;82:82–91. https://doi.org/10.1016/j.euroneuro.2024.02.003 .
doi: 10.1016/j.euroneuro.2024.02.003
pubmed: 38508100
Milaneschi Y, Simmons WK, Van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18–33. https://doi.org/10.1038/s41380-018-0017-5 .
doi: 10.1038/s41380-018-0017-5
pubmed: 29453413
Hansel B. GLP-1 agonists and suicide risk: is action needed? In: Medscape. 2023. https://www.medscape.com/viewarticle/996484 . Accessed 9 Feb 2024.
Hung A, Maciejewski ML, Berkowitz TSZ, et al. Bariatric surgery and suicide risk in patients with obesity. Ann Surg. 2023;278(4):e760–5. https://doi.org/10.1097/SLA.0000000000005825 .
doi: 10.1097/SLA.0000000000005825
pubmed: 36805965
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. JCM. 2022;12(1):145. https://doi.org/10.3390/jcm12010145 .
doi: 10.3390/jcm12010145
pubmed: 36614945
pmcid: 9821052
Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017; 1–10. https://doi.org/10.5826/dpc.0701a01
Blackburn GL, Bistrian BR, Hoag C. Hair loss with rapid weight loss. Arch Dermatol. 1977;113(2):234.
doi: 10.1001/archderm.1977.01640020106020
pubmed: 836699
Kobren SD. Misuse of ozempic for rapid weight loss can cause significant and perhaps permanent hair loss. In: Dermatology Times. 2023. https://www.dermatologytimes.com/view/misuse-of-ozempic-for-rapid-weight-loss-can-cause-significant-and-perhaps-permanent-hair-loss . Accessed 8 Feb 2024
Telogen effluvium: symptoms, causes, treatment & regrowth. In: Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/24486-telogen-effluvium . Accessed 9 Feb 2024.
Wegovy® STEP 4 Clinical Trial Results | Wegovy® (semaglutide) injection 2.4 mg. In: novoMEDLINK. https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/clinical-trial-4-results.html . Accessed 8 Feb 2024.
Shaefer CF, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818–26. https://doi.org/10.1080/00325481.2015.1090295 .
doi: 10.1080/00325481.2015.1090295
pubmed: 26371721
Daniella Nunez KL. Glucagon-like peptide 1 receptor agonists and aspiration risk. In: OpenAnesthesia. 2023. https://www.openanesthesia.org/keywords/glucagon-like-peptide-1-receptor-agonists-and-aspiration-risk/ . Accessed 8 Feb 2024.
Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol. 2023; S1542356523008698. https://doi.org/10.1016/j.cgh.2023.11.002 .
Joshi GP. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. In: American Society of Anesthesiologists. 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative . Accessed 8 Feb 2024.
Van Zuylen ML, Siegelaar SE, Plummer MP et al. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024; S0007091224000023. https://doi.org/10.1016/j.bja.2024.01.001 .
Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014; 68(5):557–67. https://doi.org/10.1111/ijcp.12361 .
Desai M. Pharmacovigilance and spontaneous adverse drug reaction reporting: challenges and opportunities. Perspect Clin Res. 2022;13(4):177. https://doi.org/10.4103/picr.picr_169_22 .
doi: 10.4103/picr.picr_169_22
pubmed: 36337368
pmcid: 9635349